Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).

Authors:
Kim H; Kim DW; Kim M; Lee Y; Ahn HK and 8 more

Journal:
Cancer

Publication Year: 2021

DOI:
10.1002/cncr.33984

PMCID:
PMC9297884

PMID:
34705268

Journal Information

Full Title: Cancer

Abbreviation: Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Disclosures Dong‐Wan Kim reports research funding from Alpha Biopharma, Amgen, AstraZeneca/Medimmune, Boehringer‐Ingelheim, Daiichi‐Sankyo, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, Chong Keun Dang, Bridge BioTherapeutics, and GSK and travel and accommodation support for advisory board meeting attendance from Amgen and Daiichi‐Sankyo. Youngjoo Lee reports participation on boards for Roche Korea and Yuhan Corporation. Hee Kyung Ahn reports payments or honoraria from Yuhan, BMS, MSD, AstraZeneca, Roche, Lilly, Pfizer, and Menarini. Myung‐Ju Ahn reports consulting fees from Alpha Pharmaceuticals and payments or honoraria from MSD, Merck, Lilly, AstraZeneca, Takeda, Yuhan, and Roche. The other authors made no disclosures."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025